Bellerophon Therapeutics (BLPH) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Bellerophon Reports 2015 Third Quarter Operational and Financial Results
November 12, 2015 6:05 AM ESTPhase 3 trial for patients with PAH on track to start enrollment by year-end
Special Protocol Assessment (SPA) issued by FDA for Phase 3 program
Company plans to continue Phase 2 testing in COPD and initiate clinical testing in Idiopathic Pulmonary Fibrosis (IPF)
HAMPTON, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) --  Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company, today reported operational and financial results for the third quarter ended September 30, 2015.
Jonathan Peacock, Chairman and Chief Executive... More
